Effects of Synbiotic Supplementation on Serum Adiponectin and Inflammation Status of Overweight and Obese Breast Cancer Survivors: A Randomized, Triple-Blind, Placebo-Controlled Trial Publisher Pubmed



Raji Lahiji M¹ ; Zarrati M¹ ; Najafi S² ; Yazdani B³ ; Cheshmazar E¹ ; Razmpoosh E^{4, 5} ; Janani L⁶ ; Raji Lahiji M¹ ; Shidfar F¹ Show Affiliations
Source: Supportive Care in Cancer Published:2021

Abstract

Purpose: Adipokines and inflammatory factors can affect breast cancer (BC) prognosis and recurrence among breast cancer survivors (BCSs). This study was to evaluate the effects of synbiotic supplementation along with a low-calorie diet on some recurrence-related factors such as adiponectin, tumor necrosis factor-alpha (TNF-α), and high-sensitivity C-reactive protein (hs-CRP) among obese and overweight BCSs. Methods: We performed a randomized, triple-blind, placebo-controlled clinical trial among 76 overweight or obese postmenopausal women with a history of hormone-receptor-positive BC. Participants were randomly divided into 2 groups to intake either 109 CFU/day synbiotic supplement or placebo (n = 38 each group) for 8 weeks. All participants were given a low-calorie diet program. The primary outcome was serum concentration of adiponectin which was measured at baseline and after 8 weeks. Results: Compared with the placebo, synbiotic intake significantly increased adiponectin (+ 13.58 (10.08, 18.17) vs. − 0.42 (− 2.90, 1.98) μg/ml; P < 0.001). In addition, synbiotic supplementation resulted in significant reduction in TNF-α levels (− 17.09 (− 32.05, − 13.60) vs. 0.20 (− 3.97, 2.00) ng/L; P < 0.001) and hs-CRP levels (− 1.14 (− 1.90, − 0.88 vs. − 0.06 (− 0.38, 0.15) mg/L; P < 0.001) compared with the placebo. Conclusions: In conclusion, 8-week synbiotic consumption by overweight and obese postmenopausal BCSs had beneficial effects on adiponectin, TNF-α, and hs-CRP. Trial registration: IRCT, IRCT20091114002709N49. Registered 18 May 2018, http://www.irct.ir: IRCT20091114002709N49. © 2021, The Author(s), under exclusive licence to Springer-Verlag GmbH, DE part of Springer Nature.